Pharmaceuticals

ApicHope

ApicHope released FY2025 Q4 earnings on April 23 After-Market (BJT), actual revenue CNY 118.27 M, actual EPS CNY -0.4463

ApicHope released FY2025 Annual Earnings on April 23 After-Market (BJT): Actual Revenue CNY 932.27 M (Forecast CNY 1.649 B), Actual EPS CNY -0.7478 (Forecast CNY 0.46)

ApicHope released FY2026 Q1 earnings on April 23 After-Market (BJT), actual revenue CNY 385.47 M, actual EPS CNY 1.3159

ApicHope FY2026 Q1 Earnings Release on April 24 After-Market (BJT)

ApicHope to Release FY2025 Annual Earnings on April 24 After-Market (BJT), Forecast Revenue CNY 1.649 B, EPS CNY 0.46

ApicHope released FY2025 Q3 earnings on October 29 Pre-Market (BJT), actual revenue CNY 230.21 M, actual EPS CNY -0.1385

ApicHope released FY2025 9 Months Earnings on October 29 Pre-Market (BJT), actual revenue CNY 814 M, actual EPS CNY -0.3012

ApicHope to Release FY2025 Q3 Earnings on October 30, Pre-Market BJT

ApicHope released FY2025 Q2 earnings on August 21 After-Market (BJT), actual revenue CNY 206.84 M, actual EPS CNY -0.2879

ApicHope released FY2025 Semi-Annual earnings on August 21 After-Market (BJT), actual revenue CNY 583.8 M, actual EPS CNY -0.1628

ApicHope to Release FY2025 Semi-Annual Earnings on August 22, 2025 (BJT)

Guangzhou Yipinhong Pharmaceutical's Innovative Drug Clinical Trial Application Accepted

Yipinhong's Gout Innovative Drug Enters Over 50% of Phase III Clinical Trials

Yipinhong's Subsidiary Obtains Registration Certificate for Cimetidine Injection

Huayuan Securities maintains Buy rating on Yipinhong

Huayuan Securities Publishes Buy Rating Research Report on Yipinhong

Huayuan Securities Maintains Buy Rating for Yipinhong

Yipinhong's Stock Soars Despite Slumping Profits Due to Bid-rigging Incident

Yipinhong's ESG Rating Dropped to B

Yipinhong's new drug included in Guangdong's innovative medical device directory

300436

601872

399006

300723

399001

300149

000001

159915

510210

ChemPartner, Cosunter, and CMES hit the daily limit up, ApicHope rose over 14%; biotechnology, shipping, and pharmaceuticals led the gains, while oil and gas, electricity, and highways saw the largest declines; the SSE Index rose 1.46%, the Shenzhen Index rose 1.7%, and the ChiNext rose 1.96%

36Kr

Cosunter

CMES

ChiNext

Shenzhen Index

ChemPartner

SSE Index

E Fund GEM ETF

Fullgoal SSE Composite ETF

The three major A-share indices all closed higher

According to the Zhitong Finance APP, ApicHope released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 814 million yuan, a year-on-year decrease of 34.35%. The net loss attributable to shareholders of the listed company was 136 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 179 million yuan. The basic loss per share was 0.3013 yuan

Zhitong

ApicHope released its performance for the first three quarters, with a net loss attributable to the parent company of 136 million yuan

ApicHope announced on its official WeChat account that the latest clinical results of deuterated benzbromarone for the treatment of gout stones have been published at ACR 2025. The study shows that the drug is effective for both treatment-naive and refractory gout stone patients, significantly reducing uric acid levels and urate crystal burden, and improving the complete dissolution rate of gout stones, providing a more effective treatment option for patients with chronic gout stones

ApicHope: The latest clinical results of the innovative drug deuterated benzbromarone for the treatment of gout stones were released at ACR 2025

ApicHope's wholly-owned subsidiary, Guangzhou ApicHope Pharmaceutical Co., Ltd., has received clinical trial approval from the National Medical Products Administration for its innovative drug APH03621 tablets, and clinical trials will be conducted soon. This drug is a novel oral, non-peptide small molecule gonadotropin-releasing hormone receptor antagonist aimed at treating endometriosis. Currently, there are no approved oral small molecule GnRH antagonists in the domestic market. This approval will have little impact on the company's short-term financial condition and operating performance

ApicHope: Subsidiary's innovative drug APH03621 tablets approved for clinical trials

According to the Zhitong Finance APP, ApicHope announced that its wholly-owned subsidiary Guangzhou Lianrui Pharmaceutical Co., Ltd. recently received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration for Methanesulfonate Neostigmine Injection. The indications for Methanesulfonate Neostigmine Injection are: anticholinesterase drug. It is used to antagonize the residual muscle relaxant effects of non-depolarizing muscle relaxants at the end of surgery, and for conditions such as myasthenia gravis, postoperative functional intestinal distension, and urinary retention

ApicHope's subsidiary obtains registration certificate for Methanesulfonic acid new strychnine injection

Asian equities are showing resilience amid mixed economic signals, with a focus on growth companies with high insider ownership. Notable companies include Meituan, ApicHope Pharmaceutical Group, and Phison Electronics, each demonstrating significant earnings growth forecasts and insider confidence. Meituan has an insider ownership of 11.2% with a projected earnings growth of 31.7% annually. ApicHope leads with 19.1% insider ownership and a forecasted growth of 99.5%. Phison Electronics, with 10.9% insider ownership, anticipates a 25.3% earnings growth. These companies reflect strong potential in the Asian market despite challenges.

Simplywall

Meituan

MEITUAN

3 Asian Growth Stocks With Strong Insider Confidence

According to the Zhitong Finance APP, ApicHope announced that its wholly-owned subsidiary Guangzhou ApicHope Pharmaceutical Co., Ltd. (abbreviated as: ApicHope Pharmaceutical) has recently received the drug clinical trial approval notice issued by the National Medical Products Administration, allowing the product to conduct clinical trials for adults with Qi deficiency cold

ApicHope: Fucanglin granules approved for clinical trials

ApicHope's wholly-owned subsidiary, Guangzhou ApicHope Pharmaceutical Co., Ltd., recently received the Supplementary Application Notification for Oseltamivir Phosphate Capsules approved by the National Medical Products Administration, adding a 45mg specification and approving changes to the excipient dosage, packaging materials, and registration standards. This approval will enrich the company's product line and positively impact sales

ApicHope's subsidiary has received the approval notice for the supplementary application of Oseltamivir Phosphate Capsules

688180

01877

688235

BGNE

06160

688331

09995

Innovative drug concept stocks rose in early trading, with RemeGen up over 14%, ApicHope and Jincheng Pharmaceutical up over 7%, Junshi Biosciences and Beigene up over 6%, and Baillie Gifford and Kangchen Pharmaceutical following suit

ApicHope(300723.SZ)